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Abstract
Huntington’s disease (HD) is a neurologic disorder that is not completely understood; its fundamental physiological
mechanisms and chemical effects remain somewhat unclear. Among these uncertainties, we can highlight information about
the concentrations of brain metabolites, which have been widely discussed. Concentration differences in affected, compared to
healthy, individuals could lead to the development of useful tools for evaluating the progression of disease, or to the advance of
investigations of different/alternative treatments. The aim of this study was to compare the thalamic concentration of
metabolites in HD patients and healthy individuals using magnetic resonance spectroscopy. We used a 2.0-Tesla magnetic
field, repetition time of 1500 ms, and echo time of 135 ms. Spectra from 40 adult HD patients and 26 control subjects were
compared. Quantitative analysis was performed using the LCModel method. There were statistically significant differences
between HD patients and controls in the concentrations of N-acetylaspartate+N-acetylaspartylglutamate (NAA+NAAG; t-test,
P,0.001), and glycerophosphocholine+phosphocholine (GPC+PCh; t-test, P=0.001) relative to creatine+phosphocreatine
(Cr+PCr). The NAA+NAAG/Cr+PCr ratio was decreased by 9% and GPC+PCh/Cr+PCr increased by 17% in patients
compared with controls. There were no correlations between the concentration ratios and clinical features. Although these
results could be caused by T1 and T2 changes, rather than variations in metabolite concentrations given the short repetition
time and long echo time values used, our findings point to thalamic dysfunction, corroborating prior evidence.
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Introduction
Huntington’s disease (HD) is a neurodegenerative
disorder with autosomal dominant inheritance and age-
dependent penetrance, caused by a CAG trinucleotide
expansion in the short arm of chromosome 4 (4p16.3)
(1,2). Normal CAG repeats range from 9 to 36, while in
patients with HD the repeats exceed 37 (3). HD is clinically
characterized as a neuropsychiatric syndrome with move-
ment disorders (chorea, dystonia, and other involuntary
movements), cognitive, and psychiatric symptoms
(psychomotor agitation, depressive symptoms, delusions,
and hallucinations). The CAG repeat size is inversely
correlated to age of onset, and directly correlated to clinical
severity (1). The diagnosis is confirmed by molecular
testing. Neuropathological alterations consist of prominent
cellular loss, especially of the medium spiny neurons in the
striatum, and atrophy of the caudate nucleus and putamen.
Other areas, such as the hippocampus, angular gyrus,
substantia nigra, cerebellum, the tuberal lateral nuclei of
the hypothalamus and the central medial-parafascicular
complex of the thalamus, are also affected (1).
The magnetic resonance spectroscopy (MRS)
technique is based on the interaction of the nuclear spin
of the atoms analyzed, subjected to an external magnetic
field, with radiofrequency pulses. These atoms emit a
measurable response signal, which can be Fourier
transformed to originate a spectrum. The spectrum profile
is directly related to the metabolite concentrations in the
sample.
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Previous MRS studies of HD evaluated various brain
regions, notably the basal ganglia (4-9), frontal lobe
(4,10), occipital lobe (5,9,11), and the thalamus (6,12).
Increases in lactate and myoinositol seem to be present in
the early stages of the disease (8,10,11), while decreased
N-acetyl aspartate (NAA) levels are consistently reported
in multiple areas of the brain (7,10,12).
The objective of this research was to assess thalamic
metabolite concentrations in patients with HD via MRS,
and to verify whether these concentrations were altered
when compared to healthy individuals. We also attempted
to correlate these findings with clinical markers of the
disease.
Material and Methods
This project was approved by the Internal Review
Board of Universidade Estadual de Campinas, SP, Brazil,
and all participants signed a written informed consent.
[1H]-MR spectra were obtained from 40 patients with HD
(13-73 years of age, mean=43±13 years, 19 women)
and from 26 healthy subjects (15-69 years of age,
mean=33±12 years, 16 women).
The control group had no history of neurological
and/or psychiatric illness. All patients had a clinical and
molecular diagnosis of HD. The HD diagnosis was made
according to established criteria, including a positive
family history; presence of a neuropsychiatric syndrome
characterized by chorea, dystonia or impaired voluntary
motor function; and cognitive or psychiatric symptoms.
Exclusion criteria were history of stroke, hypertension,
diabetes mellitus, alcohol and drug abuse, and malig-
nancy. An experienced neurologist reviewed each clinical
history and performed a neurological examination in
addition to the Unified Huntington’s Disease Rating
Scale (UHDRS) motor evaluation. Additional clinical
information is presented in Table 1. Disease onset was
characterized by the onset of any neuropsychiatric
manifestation typically found in the disease, most com-
monly chorea; however, other symptoms such as depres-
sion, change in mood or personality, and cognitive
symptoms were also taken into consideration.
Data acquisition was made using a 2.0-Tesla (T)
scanner (Elscint Prestige, Israel). A standard MRI proto-
col as described by Ruocco et al. (12) was used followed
by the MRS acquisition for all subjects. The MRS protocol
consisted of a single-voxel acquisition using PRESS
(point resolved spectroscopy sequence) with repetition
time (TR)=1500 ms, echo time (TE)=135 ms, spectral
bandwidth=1000 Hz, and 1024 complex data points. The
voxel was placed in the right thalamus, with a volume of
26262 cm3 (Figure 1).
Spectral analysis was performed, and data quantified,
using the Linear Combination of Model spectra (LCModel)
method and software (13,14). The metabolite groups
quantified with good signal-to-noise ratio (SNR) are shown
in Table 2, which correspond to the groups with the most
intense signal in the spectra. The LCModel software allows
little to no user interaction, which is an advantage for
minimizing subjective inputs, thus favoring data exchanges
and comparisons between different research groups.
Another interesting aspect of this method is that the
spectral-fitting uses characteristic spectra from every
metabolite of interest (composed of one or more peaks),
instead of individual resonance peaks from specific
chemical groups. An example of a typical spectrum from
a control subject is shown in Figure 2 (black noisy lines).
Spectra from patients were similar. Figure 2 also shows the
Table 1. Huntington’s disease (HD) patient clinical information.
Information
Number of CAG repeats 47 ± 6
Age at HD onset (years) 35 ± 12
Age at MRS scan (years) 43 ± 13
Duration of the disease (years) 8 ± 4
UHDRS motor score (points) 68 ± 32
Data are reported as means±SD. MRS: magnetic resonance
spectroscopy; UHDRS: Unified Huntington’s Disease Rating
Scale.
Figure 1. Voxel placement in the thalamus.
Table 2. Abbreviations and names of the metabolites evaluated
in this study.
Abbreviation Metabolite
GPC+PCh Glycerophosphocholine + phosphocholine
NAA+NAAG N-acetylaspartate + N-acetylaspartylglutamate
Cr+PCr* Creatine + phosphocreatine
* Internal reference.
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baseline (smoother black line) and the fitted spectrum (red
line) as calculated by LCModel.
After data analysis and processing, a two-sample t-
test was performed to compare both groups, using the
Systat software (Systat Software, Inc., USA). The
Pearson correlation coefficient between metabolite con-
centrations and other important clinical features (CAG
repeats, age, age at onset, disease duration, and UHDRS
score) was also calculated using the Systat software (15).
Both the t-test and correlation analyses were corrected
with the Bonferroni test for multiple comparisons.
Results
Given that an inherent difficulty of the in vivo MRS
technique is to obtain absolute concentration values that
may be compared reliably with values obtained using
different equipment, or under different conditions (16), we
decided to use total creatine, that is, creatine+pho-
sphocreatine (Cr+PCr) as an internal reference.
Although water spectra were available, we chose not to
use water as reference because we did not have image
data from which we could reliably estimate the water
content of the voxel. Therefore, metabolite ratios were
computed with reference to Cr+PCr.
To calculate the ratios, only metabolites whose absolute
quantification presented Cramer-Rao lower bounds smaller
than 20% (17) were used. There were 26 control individuals
and 39 patients in each metabolite group whose data
respected this criterion. Therefore, only one patient among
all participants had to be excluded from the analysis.
In addition, mean values and respective standard
deviations for the full width at half maximum (FWHM) and
the SNR parameters were determined for both patients
(FWHM=0.104±0.032 and SNR=5.9±2.4) and
controls (FWHM=0.086±0.023 and SNR=6.3±1.8).
There was no significant difference in SNR (P=0.857)
between the two groups; however, there was for FWHM
(P=0.018), which was higher for the patients than for the
controls. This was probably due to the higher incidence of
motion artifacts during scanning of the patient group,
resulting from their pathology.
Table 3 presents the mean value, standard deviation,
and respective P value (t-test, 5% significance level) of
the metabolites evaluated for both the control and patient
groups. We observed that the glycerophosphocholine+
phosphocholine (GPC+PCh)/Cr+PCr ratio increased in
patients (P=0.001) when compared with the control
group, while N-acetylaspartate+N-acetylaspartylglutamate
(NAA+NAAG)/Cr+PCr decreased (P,0.001).
The Pearson correlation coefficient was used to
verify any direct or indirect linear dependency between
metabolite concentrations and the other aforementioned
clinical features. We did not find any significant correlation
among these variables. We only found a correlation
between the number of CAG repeats and age at onset
(r=-0.579; P,0.001).
Considering that our spectra were relatively noisy,
which can be inferred from the mean FWHM and SNR, a
second data analysis was performed in a subgroup of
patients and controls. We only included spectra with
SNR.5 and FWHM,0.108 in the secondary analysis.
The patient group was reduced to 20 individuals, and the
control group to 16. This improved the mean FWHM and
SNR values for both the patient (FWHM=0.081±0.014,
SNR=7.9±1.4) and the control (FWHM=0.079±0.020,
SNR=7.4±1.3) groups. This second comparison of
metabolite contents between groups, and correlation of
metabolite content and clinical variables for the patient
group gave qualitatively the same results as those from
the whole cohort, as shown in Table 4.
Figure 2. Example spectrum from a healthy subject. A, Residual
fit. B, The black noisy line corresponds to the original spectrum
while the red line corresponds to the fitted LCModel spectrum.
Substance abbreviations are identified in Table 2.
Table 3. Metabolite concentrations relative to the Cr+PCr
concentration for the original groups (26 control subjects and
39 Huntington’s disease patients).
Group Control
(n=26)
Patients
(n=39)
P
NAA+NAAG 1.85 ± 0.21 1.59 ± 0.25 ,0.001
GPC+PCh 0.361 ± 0.046 0.411 ± 0.054 0.001
Data are reported as means±SD. P values determined with the
t-test were corrected with the Bonferroni test. For substance
abbreviations, see Table 2.
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Discussion
Although in vitro MRS has been in use for some
decades and has, therefore, become a well-established
technique, its in vivo application has several intrinsic
problems. It has markedly low sensitivity and low SNR, as
well as a high susceptibility to motion artifacts, which is of
practical relevance in HD patients. These are the reasons
why its clinical application is still limited. However, an
increasing amount of research in the medical field, notably
in neurology, has demonstrated its potential to help
diagnose several pathologies, such as cancer (e.g., 18-
20) and epilepsy (e.g., 21,22).
In this study, we found differences in the metabolic
patterns of 39 HD patients and 26 healthy individuals. A
previous study by Ruocco et al. (12), which used the
same MRS acquisition, but with a less robust spectrum
quantification analysis, and included only 22 HD patients
and 25 controls, only found a decrease in relative
concentration (NAA+NAAG)/(Cr+PCr), which was attrib-
uted to neuronal loss or dysfunction in the thalamic
region. In the present study, with almost twice as many
HD patients and a similar number of control subjects, we
found differences in both NAA+NAAG/Cr+PCr and
GPC+PCh/Cr+PCr ratios. These results may be
explained by a number of factors.
On the one hand, the groups were not appropriately
matched for age. There was a 10 year mean age
difference between groups (P=0.003, t-test). However,
the use of metabolite ratios instead of absolute metabolite
concentrations should decrease possible age effects.
Indeed, there were no significant correlations between
age and metabolite concentration ratios in either the
control or the patient group (P.0.2 for all correlations of
metabolite ratios with age in both groups).
Another possible explanation for these results is the
T1 and T2 weighting, given that relatively short TR and
long TE were used. The weightings for the measured
metabolite ratios can be estimated by using the following
expressions:
1{exp {TR=T1Metð Þ
1{exp {TR=T1CrzPCrð Þ for T1 weighting
and
exp {TE=T2Metð Þ
exp {TE=T2CrzPCrð Þ for T2 weighting, where
TR=1500 ms, TE=135 ms, and Met=NAA+NAAG or
GPC+PCh. To estimate these weightings, we searched
the literature for T1 and T2 values for NAA+NAAG,
GPC+PCh and Cr+PCr. There were no values for either
a 2.0-T field, or for the thalamus. Instead, we used values
for 1.5- and 3.0-T fields, measured for different gray
matter regions, or sometimes for a combination of both
gray and white matter (23-25). In the worst-case scenario,
we found that T1 weighting could underestimate
NAA+NAAG/Cr+PCr by 9% (1.5 T, parietal white/gray
matter), and overestimate GPC+PCh/Cr+PCr by 18%
(1.5 T, occipital lobe). However, in the best-case scenario,
NAA+NAAG/Cr+PCr remained unchanged and
GPC+PCh/Cr+PCr was overestimated by 1%. For T2
weighting, in the worst-case scenario, NAA+NAAG/
Cr+PCr could be overestimated by 41% (3.0 T, occipital
gray matter) and GPC+PCh/Cr+PCr by 39% (3.0 T,
cingulate gyrus gray matter). In the best-case scenario,
these ratios could be overestimated by 25% (1.5 T, motor
cortex gray matter) and 17% (1.5 T, occipital lobe),
respectively. In this study, we found a 9% decrease in the
NAA+NAAG/Cr+PCr ratio and a 17% increase in
GPC+PCh/Cr+PCr for the patient group compared with
the control group. Given the above T1 and T2 weighting
estimates, we cannot exclude T1 and/or T2 changes in
tissue altered by HD as responsible for these results,
rather than actual metabolite concentration changes. On
the other hand, both T1 and T2 vary a lot within brain
regions, and this is especially so in pathologies (23-25).
Moreover, we could not find T1 and T2 values for the
specific field strength used in this study, nor for the
specific brain region we evaluated. Therefore, we could
not provide a true estimate for the amount of weighting in
our data. By keeping the TE and TR fixed we established
norms for ‘‘institutional units’’, particularly using concen-
tration ratios, which are less sensitive than absolute
concentrations to relaxation effects (26).
Therefore, not excluding possible T1 and T2 changes,
which would be the same here as reported by Ruocco et
al. (12), another explanation for our results is that they
indeed demonstrate changes in metabolite concentration
(i.e., decreased NAA+NAAG/Cr+PCr and increased
GPC+PCh/Cr+PCr) in HD patients. The difference in
our results and those of Ruocco et al. (12) can be
explained by the larger sample size and the use of the
more precise LCModel quantification method. Ruocco et
al. based their research on the manual choice of peak
boundaries in the spectra followed by computation of the
area below the corresponding curve.
The HD clinical manifestations clearly imply a dys-
function of the basal ganglia-thalamocortical circuitry (27).
In a study using voxel-based morphometry, a symmetrical
atrophy of the thalamus (in particular the dorsomedial
nucleus, centromedian nucleus, parafascicular nucleus,
and ventrolateral nuclear complex) correlated with cogni-
tive performance in early onset of HD (28).
Table 4. Metabolite concentrations relative to the Cr+PCr
concentration for the reduced groups (16 control subjects and
20 Huntington’s disease patients) with higher quality spectra.
Group Control
(n=16)
Patients
(n=20)
P
NAA+NAAG 1.88 ± 0.15 1.71 ± 0.21 0.031
GPC+PCh 0.360 ± 0.035 0.421 ± 0.046 ,0.001
Data are reported as means±SD. P values determined with the
t-test were corrected by the Bonferroni test. For substance
abbreviations, see Table 2.
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Choline compounds (GPC+PCh) are among the
lipids comprising the cell membrane; therefore,
GPC+PCh abnormalities may reflect changes in cell
synthesis or destruction (29). Results including measure-
ment of choline compounds in HD are conflicting. Here we
found an increase in the thalamic GPC+PCh/Cr+PCr
ratio in HD patients. A previous study in preclinical HD
patients showed decreased choline-containing com-
pounds in the frontal lobe, which correlated with slowing
in visuomotor tasks (4). Another study found increased
choline levels in the striatum of asymptomatic HD patients
compared with controls; however, no changes were found
in symptomatic HD patients compared with controls (11).
Yet another study found a decrease in choline levels in
the striatum of akinetic HD patients compared with
controls (30). A previous study with our HD group did
not find any difference in choline levels between patients
and controls (12), but another study found increased
choline levels in the basal ganglia of HD patients
compared with controls (5). These differences are
probably related to the data acquisition and analysis
methodology that was used, the stage of disease
progression in the patients studied, and the area of the
brain (region of interest) chosen for the MRS [i.e., white
matter (4) vs deep gray matter (5,11,12,30)].
We found a reduction in the NAA+NAAG/Cr+PCr
ratio in the patient group. Prior studies showed decreased
NAA levels in the frontal lobe (10), putamen (7,8), and
thalamus (12) of HD patients. It has also been pointed out
that decreased putaminal NAA and myoinositol can
potentially be used as biomarkers for HD onset and
progression (8). Decreased NAA concentration reflects a
combination of neuronal and axonal loss as well as a
reduction in mitochondrial metabolism (31). Indeed,
mitochondrial dysfunction seems to play a key role in
HD (32). Animal models having a blockage of mitochon-
drial complex II present a neurodegenerative disease
similar to HD (33). There is also evidence that a
mechanism dependent on NMDA receptors may trigger
the medium-sized spiny neuron susceptibility to complex
II dysfunction (33).
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